Investigational drug · Phase 3
MMR vaccine
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chickenpox.
Phase 3Last checked: Nov 20, 2026Latest source record: May 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
158
Any phase or sponsor naming "MMR vaccine"
First trial start
2025
Jan 10, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MMR vaccine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chickenpox
Largest trials
Live from ClinicalTrials.gov: studies naming "MMR vaccine" as an intervention, largest first.
Neuroganics LLCIndustry
NCT05095844 · 100,000 participants (planned) · Start Mar 15, 2022 · Primary completion Apr 1, 2024
Drug: vaccinated · For: COVID-19; Vaccine Adverse Reaction; Vaccine Reaction and 10 more
Sites: Northglenn, Colorado
- Same-Day Co-Administration of Varicella and Inactivated Hepatitis A Vaccines in Children Aged 12 to 23 Months in Shandong, ChinaNot yet recruiting
Shandong UniversityAcademic, hospital or other
NCT07938151 · 35,000 participants (planned) · Start Nov 2026 · Primary completion May 30, 2028
Drug: Live Attenuated Varicella Vaccine; Inactivated Hepatitis A Vaccine · For: Hepatitis A Vaccine; Varicella Immunisation
Sites: Heze, China
- Safety Observation of Enterovirus 71 Inactivated Vaccine (Vero Cell) Combined Immunization in ShanghaiStatus unknown
Sinovac Biotech Co., LtdIndustry
NCT05166044 · 12,500 participants (planned) · Start Jan 4, 2022 · Primary completion Jun 4, 2022
Drug: EV71 Inactivated Vaccine · For: Hand, Foot and Mouth Disease
Sites: Baoshan, China; Jing’an, China; Minhang, China · 6 sites in all
- Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy InfantsPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00806195 · 7,744 participants · Start Dec 2008 · Primary completion Mar 2011
Drug: MenACWY-CRM197; DTaP (Diptheria, Tetanus, Pertussis) Vaccine and 6 more · For: Meningitis; Meningococcal Infection
Sites: Birmingham, Alabama; Dothan, Alabama; Tuscon, Arizona · 153 sites in all
- MMR at 6 Months TrialPivotal-lookingCompleted
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT03780179 · 6,540 participants · Start Apr 15, 2019 · Primary completion Jan 7, 2022
Drug: MMRvaxpro; Placebo · For: Meales-mumps-rubella Vaccine
Sites: Copenhagen, Denmark; Herlev, Denmark
- MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.Status unknown
CHU de Quebec-Universite LavalAcademic, hospital or other
NCT02712203 · 5,808 participants · Start Jul 2004 · Primary completion Jul 2010
Drug: MMR vaccine / MMRV vaccine · For: Measles
- Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and ChickenpoxPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00226499 · 5,803 participants · Start Sep 1, 2005 · Primary completion Oct 12, 2006
Drug: Priorix-tetra™; Priorix™ and 1 more · For: Varicella; Chickenpox Vaccines
Sites: Brno, Czechia; Chomutov, Czechia; Děčín, Czechia · 104 sites in all
- Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of AgePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01702428 · 5,016 participants · Start Nov 9, 2012 · Primary completion Nov 25, 2014
Drug: Priorix; M-M-R II and 3 more · For: Rubella; Measles; Mumps
Sites: Dothan, Alabama; Phoenix, Arizona; Fayetteville, Arkansas · 90 sites in all
- A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In InfantsPivotal-lookingCompleted
Novartis VaccinesNovartis (NVS)
NCT00474526 · 4,545 participants · Start Mar 2007 · Primary completion Sep 2008
Drug: Meningococcal ACWY Conjugate Vaccine; DTaP-IPV-HBV and 6 more · For: Meningitis, Meningococcal
Sites: Bessemer, Alabama; Birmingham, Alabama; Downey, California · 63 sites in all
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of LifePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01681992 · 4,538 participants · Start Oct 10, 2012 · Primary completion Feb 3, 2015
Drug: Priorix; M-M-R II and 3 more · For: Measles; Mumps; Rubella and 1 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Jonesboro, Arkansas · 81 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Resurgence of measles in the United States: Examining the outbreak, vaccine hesitancy, and future directions.
Edward M · Glob Public Health 2026
- Measles disease outbreaks are surging again globally in 2026.
Ly H · Virulence 2026
- Mumps resurgence despite MMR: Limitations of current vaccines and the need for new strategies.
Vashishtha VM, Upadhyay U · Hum Vaccin Immunother 2026
- Interplay between vaccine-related informational milestones, social media discourse, and vaccine administration rates for human papillomavirus and measles/mumps/rubella vaccines in the United States.
Annan A, Wang D, Du J, et al. · Hum Vaccin Immunother 2026
- Mumps disease and vaccination in Africa: A scoping review.
Gobe I, Mogowa T, Kadimo K, et al. · Hum Vaccin Immunother 2026
- Neurological Complications of Mumps.
Maturu MVS, Mukkala P, Santosh M, et al. · Ann Indian Acad Neurol 2026
Also in development for Chickenpox
- Marketed varicella vaccinePhase 33 trials
GSK · Chickenpox
- Investigational varicella vaccinePhase 32 trials
GSK · Chickenpox
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.